Open Orphan #ORPH – Major New Contract Win for Venn Life Sciences June 11, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that it has signed a major contract with a leading vaccine developer and one of the top pharmaceutical companies in the world. The contract with Venn Life Sciences, which is part of Open Orphan, builds on earlier successful contracts between the companies…

Open Orphan #ORPH – Major New Contract Signed With US Biotech Company for RSV Human Study & CEO Trevor Phillips to Step Down. May 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce the signing of a new contract with a US biotechnology Company for the provision of a respiratory syncytial virus (RSV) human challenge study. Highlights: Challenge study projected to deliver £3.5 million in revenue in 2020…

Irish Times – Open Orphan seals deal that could net more than €11.6m March 6, 2020 – Posted in: Open Orphan (ORPH)

by Colin Gleeson Dublin-listed pharma group announces contract with European biotech company Dublin-listed pharma services company Open Orphan has announced the signing of a new contract with a European biotech company that could yield it more than £10 million in revenue this year. Open Orphan, a European-focussed, rare and orphan drug consulting services platform, informed the Irish stock exchange of the deal for the provision of an respiratory syncytial virus (RSV) human challenge study on Friday. The…

Shares Magazine Spotlight – Open Orphan lining up for coronavirus fight February 27, 2020 – Posted in: Open Orphan (ORPH)

LSE interview – Cathal Friel refocuses Open Orphan #ORPH as he raises 5m and buys virology specialist hVIVO February 7, 2020 – Posted in: Open Orphan (ORPH)

In a wide-ranging interview with London South East, Open Orphan Executive Chairman Cathal Friel outlines his vision for the business and explains how the combined talents of Open Orphan, hVivo and Venn Life Sciences will create a soon to be profitable pharmaceutical services one-stop shop. Friel says this acquisition is the last however, as he is a major shareholder and he doesn’t want to see his own shareholding diluted along with everyone elses. The focus…

Keeping pace with Open Orphan February 3, 2020 – Posted in: Open Orphan (ORPH)

It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel. Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete the Venn Life Sciences and recent hVIVO acquisitions, Friel has invested over £2m of his own money through his investment…

Open Orphan #ORPH – Results of Placing and Subscription January 31, 2020 – Posted in: Open Orphan (ORPH)

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE…

Open Orphan (ORPH) – Proposed Placing to raise a minimum of £5 million to fund growth and convert hVIVO proposal pipeline – Posted in: Open Orphan (ORPH)

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) IS FOR INFORMATION PURPOSES ONLY…

Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission January 20, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. today. Highlights: · Completion of merger between Open Orphan and hVIVO creating a European full pharma services company in a compelling…

Irish Independent – Open Orphan signs ‘significant’ revenue generating contract January 9, 2020 – Posted in: Open Orphan (ORPH)

by Ellie Donnelly Open Orphan, a Europe-focused pharma services company specialising in rare disease and so-called orphan drugs, has signed a contract with a German-based research-driven pharmaceutical company. Open Orphan said the contract guarantees “significant” annual income, with work under the deal to commence this month. This contract will see Venn Life Sciences, part of Open Orphan, build upon its existing relationship with the German company with a new three year consultancy for Pharmacokinetic (PK)…